-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, Simcere Pharma and Vivoryon Therapeutics of Germany jointly announced that SIM0408, a new drug under development for Alzheimer's disease jointly developed by the two parties in China, has been approved by the Center for Drug Evaluation of the State Drug Administration to enter clinical trials in China
SIM0408 is a differentiated oral small molecule investigational drug candidate for Alzheimer's disease with the potential to address multiple key AD pathological mechanisms in a unique mode, including Aβ pathology, neuroinflammation and synaptic damage
SIM0408 blocks glutaminyl cyclase (QPCT) action associated with AD pathology
Reference source: [1] Simcere official website